FDA

A proposed requirement to display drug list prices in advertisements draws controversy.

Experts argue that gaps in federal food safety rules require state governments to step up.

Federal health agencies should work together to address public health problems.

Scholars caution against using the Right to Try Act to skirt regulation for regenerative therapies.

U.S. regulators should model the medical device classification process on recent tax reform.

Marchand’s argument questions key regulatory processes and ignores the net benefits of regulation.

EPA exemplifies how agency rulemaking pushes the boundaries of lawful policymaking.

Agencies should boost penalties for fatal rule violations to match the value of a statistical life.

Scholar argues that agencies should collect evidence on surgical procedures to help implement best practices.

Despite ethical concerns, scholar argues that gene editing of human embryos should not be banned.

Scholar argues that FDA should reform its regulation of algorithm-based medicine.

Scholar argues that financial regulators must be decisive yet agile when using imperfect information.